POLE exonuclease domain mutations in endometrial carcinoma: a case report

Pathologica. 2023 May;1(1):181-185. doi: 10.32074/1591-951X-872. Epub 2023 May 22.

Abstract

Endometrial carcinoma (EC) harboring POLE exonuclease domain mutations occurs in 5-15% of ECs and frequently affects young women with low body mass index (BMI). It presents at early stage as high grade endometrioid histotype with intense tumor infiltrating lymphocytes and has good clinical outcomes and favorable prognosis. In this article we report the case of a 32-year-old woman with endometriod EC (EEC) exhibiting a "ultramutated" molecular profile and an excellent prognosis despite tumor size and grading. Herein, to highlight the importance of defining POLE status in ECs for both clinical and therapeutic implications for patients.

Keywords: POLE; endometrial carcinoma; ultramutated phenotype.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Carcinoma, Endometrioid* / diagnosis
  • Carcinoma, Endometrioid* / genetics
  • Carcinoma, Endometrioid* / pathology
  • Endometrial Neoplasms* / diagnosis
  • Endometrial Neoplasms* / genetics
  • Endometrial Neoplasms* / pathology
  • Exonucleases / genetics
  • Female
  • Humans
  • Mutation
  • Poly-ADP-Ribose Binding Proteins / genetics
  • Prognosis

Substances

  • Poly-ADP-Ribose Binding Proteins
  • Exonucleases